ClinicalTrials.gg
RecruitingNCT07126106Updated Aug 17, 2025

Prospective Validation of GRADY: A Machine Learning Model for Early Sepsis and Bacteremia Detection in ICU Patients

An observational study in Bacteremia and Sepsis Bacterial, sponsored by Sisli Hamidiye Etfal Training and Research Hospital. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-17.

Sponsored by Sisli Hamidiye Etfal Training and Research Hospital · Observational

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Feb 2025; still recruiting 1 year 9 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
55
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to prospectively validate the GRADY prediction models, which use machine learning algorithms to estimate the risk of gram-negative bacteremia and sepsis in intensive care unit (ICU) patients based on routinely collected vital signs and laboratory data. Sepsis, a life-threatening condition associated with high ICU mortality, requires early diagnosis and treatment-yet current diagnostic methods relying on blood cultures are time-consuming. Existing scoring systems such as SOFA, SIRS, and NEWS2 often lack sufficient sensitivity and specificity in early sepsis detection. Unlike traditional tools, the GRADY models seek to provide earlier and more accurate risk stratification. This study will compare the clinical performance of GRADY models against standard scoring systems and explore their integration as early warning tools to support rapid intervention and improve outcomes in critical care.

Read the detailed description

Sepsis is a common and critical clinical syndrome encountered in intensive care units (ICUs), associated with high rates of mortality and morbidity. It is defined as a life-threatening organ dysfunction caused by a dysregulated host response to infection (Sepsis-3 definition). Early diagnosis and prompt initiation of appropriate treatment before the onset of organ failure are vital to reducing mortality and morbidity. Gram-negative bacteremia is a significant cause of sepsis cases. Early initiation of appropriate empirical or targeted antibiotic therapy in bacteremia cases plays a pivotal role in patient prognosis. However, the diagnosis of gram-negative bacteremia is generally based on blood culture results, which may take 24-72 hours. The delay during this period is considered a major contributor to increased mortality risk.

In recent years, machine learning-based prediction models have been increasingly used as decision support tools in healthcare. The GRADY prediction models, developed retrospectively in our hospital, aim to predict the risk of sepsis due to gram-negative bacteremia using vital signs and laboratory parameters obtained during routine clinical monitoring. However, prospective validation of these models is essential prior to their integration into clinical practice.

The rationale of this study is to facilitate early identification of ICU patients at risk for bacteremia or sepsis to enable prompt initiation of treatment. Reducing mortality and morbidity through early detection may help alleviate the burden on healthcare systems. Moreover, supporting current clinical practices with early prediction models may enhance decision-making efficiency. The use of early warning systems and machine learning-based algorithms may improve clinical predictive power and allow for timely interventions by clinicians. This study aims to evaluate the diagnostic accuracy and clinical applicability of GRADY models through prospective validation. In this regard, the findings may contribute to the development of new approaches for sepsis and bacteremia management in critical care settings.

In current clinical practice, scoring systems such as the Sequential Organ Failure Assessment (SOFA), Systemic Inflammatory Response Syndrome (SIRS), and National Early Warning Score 2 (NEWS2) are used to define sepsis and to identify high-risk patients early. However, these scoring systems are based on a limited set of clinical and laboratory parameters and have shown suboptimal sensitivity and specificity in early sepsis diagnosis according to various studies. This limitation may reduce the chance of early intervention and negatively affect patient outcomes. GRADY models aim to offer risk prediction based on routinely collected clinical and laboratory data using machine learning algorithms, providing an alternative to conventional scoring systems. This study will compare the diagnostic accuracy and clinical performance of GRADY models with widely used scoring systems such as SOFA, SIRS, and NEWS2.

Currently, there are only a limited number of validated and widely accepted scoring systems available for the early identification of bacteremia. The Pitt Bacteremia Score was developed to predict short-term mortality in patients diagnosed with bacteremia and has been validated in several studies. Unlike the Pitt score, GRADY models aim to predict the risk of bacteremia and sepsis in the early period before diagnosis using routine clinical and laboratory data. Although the two systems do not serve exactly the same purpose, Pitt Bacteremia Scores will be calculated for all patients in this study, and the potential relationship with high-risk classification by the GRADY model will be evaluated statistically.

02

Conditions studied

  • Bacteremia
  • Sepsis Bacterial

Keywords

  • Bloodstream Infection
  • sepsis
  • Machine Prediction Methods
  • external validation
03

In context

Bacteremia

297 studies on the registry are indexed under Bacteremia; 51 are open to participants now.

This study's planned enrollment of 55 is below the median of 300 across 125 observational studies indexed under Bacteremia.

Browse Bacteremia studies →

Lead sponsor

Sisli Hamidiye Etfal Training and Research Hospital is the lead sponsor of 114 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients over the age of 18 who are suspected of having bacteremia while being treated in intensive care will be included in the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18 years or older
  • ICU stay of 48 hours or longer
  • Patients from whom blood cultures were obtained during routine monitoring
  • Signed form

Exclusion criteria

Exclusion Criteria:

  • Patients younger than 18 years
  • ICU stay shorter than 48 hours
  • Patients without blood cultures
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
55 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Gram(-) negative bacteremia

    Gram (-) bacteria growth in blood culture

    Time frame: 1-28 days

Secondary outcomes

  1. SOFA

    The Sequential Organ Failure Assessment (SOFA) score is a clinical tool that evaluates the extent of a patient's organ dysfunction based on six parameters - respiratory function (PaO₂/FiO₂), coagulation (platelet count), liver function (bilirubin level), cardiovascular status (mean arterial pressure or vasopressor use), central nervous system function (Glasgow Coma Scale), and renal function (creatinine level or urine output) - and it will be assessed at the time of patient admission.

    Time frame: it will be assessed at the time of patient admission.

  2. SIRS

    The Systemic Inflammatory Response Syndrome (SIRS) criteria are used to identify a generalized inflammatory state based on four parameters - body temperature, heart rate, respiratory rate or PaCO₂, and white blood cell count

    Time frame: they will be assessed at the time of patient admission

  3. NEWS-2

    The National Early Warning Score 2 (NEWS-2) is a clinical scoring system used to assess the severity of a patient's acute illness based on six parameters - respiratory rate, oxygen saturation, systolic blood pressure, heart rate, level of consciousness or new confusion, and temperature

    Time frame: it will be assessed at the time of patient admission.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07126106
Responsible party
AHMET DOGUKAN (principal investigator, Sisli Hamidiye Etfal Training and Research Hospital) — Principal investigator
First posted
Aug 17, 2025
Start date
Feb 1, 2025
Primary completion
Dec 1, 2025 (estimated)
Completion
Jan 1, 2026 (estimated)
Last update
Aug 17, 2025

Study contacts

okan derin
Contact
okanderin@gmail.com
+905053580264
ahmet doğukan bayrak
Contact
dogukan9653@gmail.com
+905453511707

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion